exclusion criteria. Seventh TNM edition was used. Totally 168 patients' demographic data, surgery types, clinical and pathological stage, pre-operative SUVmax and C/T ratio was recorded. Differences between patients with recurrence after surgery and without recurrence was demonstrated. Survival rates were analysed by divided into 3 groups according to C/T ratio (0.25-0.5, 0.5-0.75, 0.75-1.0) and cutoff value 50% of C/T ratio. Result: Two groups (C/T<0.5 and C/ T¼0.5-1) did not differ according to comparable factors like visceral pleural invasion, subtype of adenocarcinoma, median SUVmax. Median follow up time was 35 months. 54 patients were died of whom 8 (68%) patients were in C/T ratio<0.5 and 46 patients (67.8%) were in C/T¼0.5-1 group. OS was 44.9±5.07 and PFS was 50.8±5.42 in C/ T<0.5 group. OS was 69.7±3.34 and PFS was 77.2±3.23 in C/T¼0.5-1 group (p>0.05). Three-year survival rate was 50% for C/T <0.5 and 72% for C/T¼0.5-1 group (p>0.05).
Background: Because of the risk of recurrence, lobectomy is indicated even for small lung cancers. If we could accurately predict and classify noninvasive small lung cancers on CT images using deep learning algorithm prior to surgery, a more refined selection of candidates who would benefit from limited resection without increasing the risk of recurrence would be possible. The purpose of this study was to evaluate the ability of an artificial intelligence (deep learning algorithm) to predict pathological noninvasiveness of T1 non-small cell lung cancer (NSCLC) using computed tomography (CT) images. Method: 468 preoperative CT images of NSCLC smaller than 3 cm, resected at our institution from 2008 to 2015 were used to train and validate the deep learning algorithm. Noninvasiveness was defined as the absence of nodal involvement, vascular invasion, and lymphatic invasion, and NSCLCs were classified as either noninvasive or invasive according to the pathological reports. A deep 3D convolutional neural network (CNN) was trained using 5-fold cross-validation method. To normalize input data, we rescaled CT image to let one voxel size be represented as (1mm,1mm,1mm) . Input cube size was (32mm, 32mm, 32mm). Horizontal flip and vertical flip augmentation were applied, and maxpooling and dropout layer were used to avoid overfitting. Receiver operating characteristic (ROC) curves and areas under the curve (AUCs), accuracy, and sensitivity/specificity were used to assess the performance of 3D CNN. We also added tumor size as an external feature to the 3D CNN model and evaluated the performance of the combined model using Xgboost classifier. Result: 157 out of 486 samples (33.5%) were invasive. A subsample group composed of 10% of the data (32 noninvasive and 16 invasive samples) was retained for the validation set. The 3D CNN showed an AUC of 0.826, 77.08% accuracy, 68.7% sensitivity, and 81.2 % specificity. Adding tumor size to the 3D CNN model showed an AUC of 0.855, 81.25% accuracy, 87.5% sensitivity, and 78.1% specificity. Background: Approximately 20e25% of patients with NSCLC are diagnosed with early or localized disease, which has a relapse rate of 30e80% with surgery. Although neoadjuvant chemotherapy can reduce the risk of relapse, it only provides a pathological complete response (pCR; no viable tumor cells) rate of 4%. The neoadjuvant setting presents abundant tumor-associated neoantigens derived from the primary tumor that may allow immunotherapy to prime a long-lasting immune response. Clinical trial results support the use of immuno-oncology agents as neoadjuvant treatment for early-stage NSCLC. In a pilot study in patients with untreated, surgically resectable early-stage (stage IeIIIA) NSCLC, nivolumab (a fully human PD-1 immune checkpoint inhibitor antibody) administered as neoadjuvant treatment (3 mg/kg for 2 cycles during the 4 weeks prior to surgery) induced a pCR in 10% of patients and a major pathological response (MPR; 10% residual viable tumor cells in resected primary tumor) in 45% of patients, did not delay surgery, and was associated with an acceptable safety profile. Combining immuno-oncology agents with distinct mechanisms of action, such as PD-1 and CTLA-4 inhibitors, offers the possibility of a synergistic response and may improve antitumor activity compared with either agent alone. The combination of an immuno-oncology agent and chemotherapy may also offer synergistic activity, given that chemotherapy results in tumor cell death and subsequent antigen release that can activate an immune response. Promising results have been noted with nivolumab plus ipilimumab (a CTLA-4 immune checkpoint inhibitor antibody) and nivolumab plus chemotherapy in patients with treatment-naïve stage IIIB/IV NSCLC in the multicohort phase 1 CheckMate 012 study. CheckMate 816 (NCT02998528) is a phase 3 study evaluating nivolumab plus ipilimumab, nivolumab plus platinum-doublet chemotherapy, and platinum-doublet chemotherapy as neoadjuvant treatment for earlystage NSCLC. Method: Approximately 642 patients aged 18 years with early-stage (stages IBeIIIA) resectable NSCLC, ECOG performance status 0e1, pulmonary function capable of tolerating lung resection, and available lung tumor tissue will be enrolled in North America, South America, Europe, Asia, and Africa. Patients are ineligible if they have active autoimmune disease or had received prior treatment with immune checkpoint inhibitors. Patients will be randomized (1:1:1) to receive neoadjuvant nivolumab plus ipilimumab, nivolumab plus platinum-doublet chemotherapy, or platinumdoublet chemotherapy. Primary endpoints are event-free survival and pCR. Key secondary endpoints are overall survival and MPR (<10% residual tumor in lung and lymph nodes). Background: The purpose of this study is to clarify the prognostic value of lymphovascular invasion (LVI) in patients with surgically resected T1-3N0 non-small cell lung cancer (NSCLC) according to the eighth edition of the TNM Classification of the American Joint Committee on Cancer (AJCC). Method: A total of 442 NSCLC patients who received curative surgery and were confirmed with pathologic T1-3N0 between March 2000 and August 2015 were reviewed. The pathological stages were re-evaluated according to the eighth edition of the TNM Classification of the AJCC. Result: The 5-year recurrence-free survival (RFS) rate for total cohort was 69.7%, and the 5-year overall survival (OS) rate was 78.0%. LVI was present in 89 patients (19.9%). The presence of LVI decreased the 5-year RFS rate significantly (47.5% vs. 72.3%, p < 0.001) and the 5-year OS rate (62.5% vs. 81.1%, p < 0.001). The differences between LVI group and non-LVI group were more remarkable in T2a-bN0 staged patients compared with T1a-c staged patients (T1a-c patients: 63.6% vs. 78.0%, p ¼ 0.004; T2a-b patients: 31.7% vs. 64.9%, p ¼ 0.027, respectively). Multivariate analysis revealed that the presence of LVI was a significant predictor for RFS (p < 0.001) but an insignificant factor for OS. In T2a-bN0 staged patients, the 5year OS rate was significantly lower in patients with LVI than in patients without LVI (50.0% vs. 74.4%, p ¼ 0.045), whereas T1a-c staged patients did not show a significant difference in 5-year OS according to the presence of LVI (p ¼ 0.196). Conclusion: LVI is a significant associated factor for RFS in patients with stage T1-3N0 NSCLC. Prognostic impact of LVI is more remarkable in patients with more than T2N0 stage compared to patients with the T1N0 disease. Keywords: non small cell lung cancer, lymphovascular invasion, patterns of recurrence P2.16-05 Hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK Genes Plays a Role in NSCLC Pathogenesis M. Kontic, 1 D. Jovanovic, 1 S. Ognjanovic 2 1 Oncology, Clinic for Pulmonology, Clinical Centre of Serbia, Belgrade/RS, 2 Mayo Graduate School, Mayo Clinic, Rochester, MN/US Background: A number of genes have been reported as aberrantly methylated in lung tumors. Here, we investigate the relationship between gene methylation in lung tumors relative to matching normal lung tissue, and whether DNA methylation changes can be detected in paired blood samples. Method: Primary tumor samples (n¼65), corresponding nonmalignant lung tissues (n¼65) and maching blood samples (n¼51) were obtained from NSCLC patients undergoing curative resectional surgery. Using bisulfite pyrosequencing, CpG methylation was quantified at seven genes (RASSF1A, CDH13, MGMT, ESR1, HOXA9, SOX1 and DAPK) in lung tumor, matching pathologically normal lung tissue, and circulating blood samples. We wanted to determine whether these methylation changes are specific to lung tumors, and test whether these changes are detectable in patients' blood samples. We also analyzed possible associations between DNA methylation and clinicopathologic features. Result: We observed that genes SOX1, RASSF1A, HOXA9, CDH13 and DAPK were significantly hypermethylated in lung tumors compared to match normal tissue. However, these changes could not be detected in patients' blood samples, indicating a low feasibility of detecting lung cancer by analyzing these genes in a blood-based test. We confirmed that hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK play a role in NSCLC pathogenesis, but also showed that these genes are not suitable markers for early detection of NSCLC. Lastly, we found that histology and gender were associated with methylation at the CDH13 gene, while stage was associated with methylation at MGMT. Conclusion: Our results show higher methylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK genes in lung tumors compared to matching normal lung tissue. The lack of reflection of these methylation changes in blood samples from patients with NSCLC indicates their poor suitability for a screening test. Background: Increasing patients were diagnosed with stage I nonsmall cell lung cancer (NSCLC), and in 30% of diagnosed patients, recurrence will develop within 5 years. Optimal postoperative adjuvant therapy is still ambiguous for stage I NSCLC. Here, we aimed to develop and validate a feasible tool for recurrent risk assessment of stage I NSCLC. Method: This retrospective study incorporated the gene expression profiles from 14 public NSCLC cohorts, including 13 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort. In discovery phase, multiple eligible microarray data sets were used to select statistically significant genes thought to be predictive by two algorithms, Least Absolute Shrinkage and Selector Operation and Support Vector Machine-Recursive Feature Elimination. In the training phase, candidate genes were used to generate a recurrence related signature in TCGA cohort by penalized Cox regression.
